Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous memory lymphocyte therapy
- Development stage
- Phase 1
- Lead developer
- Newish Technology
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous memory lymphocyte therapy (NewishT) is an investigational cell therapy developed by Newish Technology (Beijing) Co., Ltd. It involves the intravenous infusion of a patient's own (autologous) memory lymphocytes. The therapy is being evaluated in a Phase 1 clinical study for its safety and efficacy in patients with hepatocellular carcinoma who are at high risk of recurrence after radical resection.
- Brand names
- NewishT
- Other names
- Autologous memory lymphocyte Injection
Beyond the preview
Go deeper on Autologous memory lymphocyte therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous memory lymphocyte therapy.